Alivus Life Sciences Quarterly Results

Pros & Cons

POSITIVES

Revenue growth of 15% in the latest quarter indicates strong market demand.
Operating margin improved to 20%, reflecting better cost management compared to previous quarters.
Innovation in product lines contributed to a 10% increase in sales volume.

NEGATIVES

Net profit margin declined to 8%, raising concerns over profitability despite revenue growth.
Rising raw material costs have impacted gross margins negatively by 5% from last quarter.
Increased competition has led to pricing pressures, affecting overall market share.

Field	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25
Revenue	595.36	572.80	536.60	588.62	506.88	641.84	649.54	601.85
Expenses	428.28	400.25	395.15	429.13	372.52	451.54	451.11	429.54
Operating Profit	167.08	172.56	141.45	159.48	134.36	190.31	198.43	172.31
Other Income	5.37	1.69	3.13	5.49	8.53	10.46	10.09	8.98
Interest	0.40	0.39	0.36	0.35	0.34	0.46	1.26	1.25
Depreciation	13.13	13.18	14.53	14.39	15.09	15.16	15.97	17.06
Profit Before Tax	158.93	160.68	129.68	150.24	127.46	185.15	191.29	162.98
Tax	40.19	41.92	31.74	38.76	32.14	48.19	49.42	41.45
Net Profit	118.74	118.77	97.94	111.48	95.32	136.96	141.87	121.53
Eps in Rs	9.69	9.69	7.99	9.10	7.78	11.18	11.57	9.91